Key Metrics
11.14
Heat Index-
Impact LevelMedium
-
Scope LevelNational
-
Last Update2025-12-29
Key Impacts
Positive Impacts (2)
Chinese Distressed‐Asset Management Companies
Legal & Restructuring Advisory Services Firms in China
Negative Impacts (6)
On-shore China High-Yield Pharmaceutical Corporate-Bond Index
ST长药
Chinese Small-cap Pharmaceutical Equities
"ST"-labelled A-share Stocks
Hubei Regional Commercial Banks
Audit & Accounting Service Firms in China
Total impacts: 8 |
Positive: 2 |
Negative: 6
Event Overview
The event highlights the regulatory scrutiny and financial challenges faced by a company. It involves the rejection of a reorganization application, the termination of a pre-restructuring process, and an investigation into alleged financial misreporting, all leading to potential delisting and bankruptcy.
Collect Records
ST长药重整申请被拒并面临退市风险
2025-12-29 20:18
ST长药收到湖北省十堰市中级人民法院的裁定，不予受理对公司的重整申请，并终结预重整程序。法院同时裁定终止湖北长江星医药股份有限公司等七家公司的实质合并重整程序，并宣告这些公司破产。因涉嫌财务数据虚假记载，公司被中国证监会立案调查，可能触及重大违法强制退市情形。公司股票自2025年4月22日起被实施退市风险警示和其他风险警示。
ST长药因涉嫌财务数据虚假记载被中国证监会立案调查
2025-12-03 18:20
ST长药于2025年11月7日收到中国证监会的《立案告知书》，因涉嫌财务数据虚假记载被立案调查。若最终认定的事实触及重大违法强制退市情形，公司股票将被强制退市。
Total records: 2